Status:
COMPLETED
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0....
Eligibility Criteria
Inclusion
- Age: 30 years or older.
- Primary open-angle glaucoma (POAG) or ocular hypertensive in at least one eye.
- Best corrected visual acuity at least 20/40 in at least one eye.
Exclusion
- History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy.
- History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).
- History or signs of intraocular trauma.
- Any abnormality preventing reliable applanation tonometry.
- Current use of any ophthalmic or systemic steroid which may interfere with this investigation.
- Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00811850
Start Date
December 1 2008
End Date
December 1 2009
Last Update
April 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indianapolis, Indiana, United States